Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer.

被引:40
作者
Kuroi K. [1 ]
Toi M. [1 ]
Tsuda H. [1 ]
Kurosumi M. [1 ]
Akiyama F. [1 ]
机构
[1] Japan Breast Cancer Research Group, Cancer Institute.
关键词
Primary systemic therapy; Neoadjuvant chemotherapy; Preoperative chemotherapy; Pathologic complete response; Breast cancer;
D O I
10.2325/jbcs.13.38
中图分类号
学科分类号
摘要
BACKGROUND: Emerging evidence suggests that induction of pathologic complete response (pCR) after primary systemic therapy (PST) is, at least to some extent, predictive of survival. However, standards for processing surgical specimens and for histopathologic evaluation of the pathologic response to therapy appear to be lacking. METHODS: To perform a systematic review of representative articles on this topic, a computerized (MEDLINE) search was undertaken followed by a manual search based on the reference lists of the publications identified. RESULTS: Several classification systems have been used to assess pathologic response to PST, the term pCR has not been applied in a consistent standardized manner, and only limited information is available about the reliability and validity of these classification systems. However, definitions of pCR can be summarized as follows: near pCR, only focal invasive tumor residues in the removed breast; quasi pCR, total or near total disappearance of invasive tumor in the removed breast; pCRinv, only in situ tumor residual in the removed breast; comprehensive pCR, no evidence of residual invasive tumor in the removed breast; strict pCR, disappearance of all tumor cells in the removed breast; comprehensive pCR (br+n), no evidence of residual invasive tumor in the breast and axillary nodes; strict pCR (br+n), no malignant tumor cells in the removed breast and axillary nodes. Comparison of the use of the term "pCR" in various trials reveals that it is not applied equivalently in these studies. CONCLUSION: Assessment of pCR needs to be standardized, with verification for reliability and validity. For now, the non-equivalency in the definition of pCR should be taken into account when comparing the results of PST.
引用
收藏
页码:38 / 48
页数:10
相关论文
共 444 条
[1]  
Kaufmann M(2003)International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations J Clin Oncol 21 2600-2608
[2]  
von Minckwitz G(2004)Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26–28, 2003, Philadelphia, Pennsylvania Cancer 100 2512-2532
[3]  
Smith R(2004)Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer Clin Cancer Res 10 3249-3261
[4]  
Valero V(2003)Is there still a role for neoadjuvant therapy in breast cancer? Crit Rev Oncol Hematol 45 77-90
[5]  
Gianni L(2004)Neoadjuvant chemotherapy for primary breast cancer: lessons learned and opportunities to optimize therapy Ann Surg Oncol 11 3S-8S
[6]  
Eiermann W(1998)Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672-2685
[7]  
Howell A(1998)Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer Am J Surg 176 502-509
[8]  
Costa SD(1999)Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 460-469
[9]  
Beuzeboc P(2002)Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel J Clin Oncol 20 1456-1466
[10]  
Untch M(1999)Does the degree of cell lesion in breast cancer after inductive chemotherapy have any prognostic value? Acta Oncol 38 949-953